3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.
8 citations
,
January 2023 in “Journal of Clinical and Translational Hepatology” This study examines the development and application of cultured models for gallbladder carcinoma and highlights innovations and challenges in constructing effective in vitro growth models for cancer research.
2 citations
,
October 2015 in “The New England Journal of Medicine” This case report describes a 57-year-old woman with hirsutism, hair loss, and vocal changes, who was found to have elevated testosterone levels but normal dehydroepiandrosterone sulfate levels.
81 citations
,
February 2019 in “Experimental & Molecular Medicine” This review examines PAK4 signaling pathways in prostate cancer, Parkinson's disease, and melanogenesis, focusing on the potential role of the PAK4-CREB axis, without reporting new clinical results.
23 citations
,
February 1979 in “Veterinary Clinics of North America: Small Animal Practice” This review discusses the physicochemical properties, binding mechanisms, and factors affecting corticosteroid-binding globulin (CBG) functions, but reports no new clinical results.